blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3197474

EP3197474 - INHIBITORS OF NF KAPPA-B ACTIVITY FOR TREATMENT OF DISEASES AND DISORDERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.04.2024
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  05.05.2023
FormerGrant of patent is intended
Status updated on  19.10.2022
FormerExamination is in progress
Status updated on  26.09.2022
FormerGrant of patent is intended
Status updated on  18.05.2022
FormerExamination is in progress
Status updated on  04.04.2022
FormerGrant of patent is intended
Status updated on  23.11.2021
FormerExamination is in progress
Status updated on  25.09.2019
FormerRequest for examination was made
Status updated on  04.07.2017
FormerThe international publication has been made
Status updated on  14.04.2017
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
Bhatnagar, Rajendra, Sahai
173 Los Robles Drive
Burlingame, CA 94010 / US
[2017/31]
Inventor(s)01 / see applicant
...
 [2017/31]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2023/23]
Former [2017/31]Brasnett, Adrian Hugh, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date15844064.425.09.2015
[2017/31]
WO2015US52467
Priority number, dateUS201462055982P26.09.2014         Original published format: US 201462055982 P
[2017/31]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2016049580
Date:31.03.2016
Language:EN
[2016/13]
Type: A2 Application without search report 
No.:EP3197474
Date:02.08.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 31.03.2016 takes the place of the publication of the European patent application.
[2017/31]
Type: B1 Patent specification 
No.:EP3197474
Date:07.06.2023
Language:EN
[2023/23]
Search report(s)International search report - published on:US19.05.2016
(Supplementary) European search report - dispatched on:EP19.07.2018
ClassificationIPC:C07K5/083, C07K7/06, A61K38/00, A61P29/00
[2018/25]
CPC:
C07K5/0806 (EP,US); C07K5/10 (US); A61P17/00 (EP);
A61P25/04 (EP); A61P29/00 (EP); A61P43/00 (EP);
C07K7/06 (EP,US); A61K38/00 (EP,US) (-)
Former IPC [2017/31]A61K38/00, A61P29/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/31]  
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:INHIBITOREN DER NF-KAPPA-B-AKTIVITÄT ZUR BEHANDLUNG VON KRANKHEITEN UND LEIDEN[2017/31]
English:INHIBITORS OF NF KAPPA-B ACTIVITY FOR TREATMENT OF DISEASES AND DISORDERS[2017/31]
French:INHIBITEURS DE L'ACTIVITÉ DE NF-KAPPA-B POUR LE TRAITEMENT DE CERTAINES MALADIES ET DE CERTAINS TROUBLES[2017/31]
Entry into regional phase19.04.2017National basic fee paid 
19.04.2017Search fee paid 
19.04.2017Designation fee(s) paid 
19.04.2017Examination fee paid 
Examination procedure13.04.2017Date on which the examining division has become responsible
19.04.2017Examination requested  [2017/31]
15.04.2019Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
13.06.2019Amendment by applicant (claims and/or description)
30.09.2019Despatch of a communication from the examining division (Time limit: M04)
30.01.2020Reply to a communication from the examining division
06.04.2020Despatch of a communication from the examining division (Time limit: M06)
15.10.2020Reply to a communication from the examining division
24.11.2021Communication of intention to grant the patent
01.04.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
19.05.2022Communication of intention to grant the patent
26.09.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.10.2022Communication of intention to grant the patent
22.02.2023Fee for grant paid
22.02.2023Fee for publishing/printing paid
22.02.2023Receipt of the translation of the claim(s)
Opposition(s)08.03.2024No opposition filed within time limit [2024/20]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
13.06.2019Request for further processing filed
13.06.2019Full payment received (date of receipt of payment)
Request granted
09.07.2019Decision despatched
Fees paidRenewal fee
08.12.2017Renewal fee patent year 03
11.09.2018Renewal fee patent year 04
13.09.2019Renewal fee patent year 05
14.09.2020Renewal fee patent year 06
10.09.2021Renewal fee patent year 07
11.08.2022Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
30.09.201703   M06   Fee paid on   08.12.2017
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY25.09.2015
HU25.09.2015
CZ07.06.2023
ES07.06.2023
HR07.06.2023
MC07.06.2023
PL07.06.2023
RO07.06.2023
RS07.06.2023
SK07.06.2023
SM07.06.2023
TR07.06.2023
NO07.09.2023
GR08.09.2023
IE25.09.2023
IS07.10.2023
[2026/04]
Former [2025/39]CY25.09.2015
HU25.09.2015
CZ07.06.2023
ES07.06.2023
HR07.06.2023
MC07.06.2023
PL07.06.2023
RO07.06.2023
RS07.06.2023
SK07.06.2023
SM07.06.2023
NO07.09.2023
GR08.09.2023
IE25.09.2023
IS07.10.2023
Former [2025/36]CY25.09.2015
CZ07.06.2023
ES07.06.2023
HR07.06.2023
MC07.06.2023
PL07.06.2023
RO07.06.2023
RS07.06.2023
SK07.06.2023
SM07.06.2023
NO07.09.2023
GR08.09.2023
IE25.09.2023
IS07.10.2023
Former [2024/33]CZ07.06.2023
ES07.06.2023
HR07.06.2023
MC07.06.2023
PL07.06.2023
RO07.06.2023
RS07.06.2023
SK07.06.2023
SM07.06.2023
NO07.09.2023
GR08.09.2023
IE25.09.2023
IS07.10.2023
Former [2024/28]CZ07.06.2023
ES07.06.2023
HR07.06.2023
MC07.06.2023
PL07.06.2023
RO07.06.2023
RS07.06.2023
SK07.06.2023
SM07.06.2023
NO07.09.2023
GR08.09.2023
IS07.10.2023
Former [2024/10]CZ07.06.2023
ES07.06.2023
HR07.06.2023
PL07.06.2023
RO07.06.2023
RS07.06.2023
SK07.06.2023
SM07.06.2023
NO07.09.2023
GR08.09.2023
IS07.10.2023
Former [2024/08]ES07.06.2023
HR07.06.2023
RS07.06.2023
SK07.06.2023
SM07.06.2023
NO07.09.2023
GR08.09.2023
Former [2023/51]ES07.06.2023
HR07.06.2023
RS07.06.2023
NO07.09.2023
GR08.09.2023
Former [2023/50]ES07.06.2023
NO07.09.2023
GR08.09.2023
Former [2023/48]ES07.06.2023
NO07.09.2023
Former [2023/46]ES07.06.2023
Documents cited:Search[XDAI] US2006293228  (BHATNAGAR RAJENDRA S et al.) [XD] 1-3,6-10,12-15 * the whole document, in particular paragraphs [0006], [0035], [0036], [0052], [0211], [0220]; claim 32; table 3;; sequences 3, 41 *[A] 4,5 [I] 11
 [XI] WO0226935  (UNIV CALIFORNIA et al.) [X] 1,2,6-10,12-15 * the whole document, in particular page 1, lines 9-16; page 3, line 26 to page 4, line 21; page 6, lines 27-30; claims 1-8;; sequences 1-3 *[I] 11
 [A]   S C GUPTA ET AL: "Inhibiting NF-kB activation by small molecules as a therapeutic strategy", BIOCHIMICA ET BIOPHYSICA ACTA (BBA), vol. 1799, no. 10-12, 1 October 2010 (2010-10-01), pages 775 - 787, XP055015585, ISSN: 1874-9399, DOI: 10.1016/j.bbagrm.2010.05.004 [A] 1-15 * the whole document, in particular abstract; table 1 *

DOI:   http://dx.doi.org/10.1016/j.bbagrm.2010.05.004
 [A]   T D GILMORE ET AL: "Inhibitors of NF-kB signaling: 785 and counting", ONCOGENE, vol. 25, no. 51, 30 October 2006 (2006-10-30), London, pages 6887 - 6899, XP055340606, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1209982 [A] 1-15 * the whole document, in particular abstract; table 1 *

DOI:   http://dx.doi.org/10.1038/sj.onc.1209982
 [A]   K. KAVITHA ET AL: "Cytomodulin-1, a synthetic peptide abrogates oncogenic signaling pathways to impede invasion and angiogenesis in the hamster cheek pouch carcinogenesis model", BIOCHIMIE, vol. 102, 1 July 2014 (2014-07-01), FR, pages 56 - 67, XP055474072, ISSN: 0300-9084, DOI: 10.1016/j.biochi.2014.02.010 [A] 1-15 * the whole document, in particular abstract; page 57, column 1, lines 38-40; page 65, column 2, lines 9-15 *

DOI:   http://dx.doi.org/10.1016/j.biochi.2014.02.010
International search[XY] US2011015138  (KUFE DONALD W et al.) [X] 1, 2, 17, 18, 23 * Claim 1, para [0003], [0009], [0010], [0014], [0058], [0156], [0158], SEQ ID NOs: 50-52 *[Y] 3-9, 12-14, 19, 22, 24, 29- 32
 [Y] WO9516709  (BIOGEN INC et al.) [Y] 3-9, 14, 19, 24-25, 29-32 * page 4 In 28-35, page 24, In 33-35 - page 25 In 1-4, Fig. 1D *
 [Y] US2011150828  (GALIPEAU JACQUES et al.) [Y] 25 * para [0004], [0005] *
 [Y] US2010215636  (HIGAZI ABD AL-ROOF et al.) [Y] 3-9, 14, 19, 24, 26-27, 29-32 * SEQ ID NO:4, para [0011], [0012], [0019], [0064], [0071] *
 [Y]   NEIDERBERGER ET AL.: "The IKK-NF-kB pathway: a source for novel molecular drug targets in pain therapy?", vol. 22, no. Issue 10, 17 June 2008 (2008-06-17), pages 3432 - 3442, XP055009933 [Y] 12-14 * page 3434 col 2 para 4 *

DOI:   http://dx.doi.org/10.1096/fj.08-109355
 [Y]   BOWEN ET AL.: "New Pathways for Alimentary Mucositis", J ONCOL ONLINE PUBLICATION, vol. 907892, 23 September 2008 (2008-09-23), pages 1 - 7, XP055419818 [Y] 22 * , page 2 col 1 para 2, Table 2 *

DOI:   http://dx.doi.org/10.1155/2008/907892
 [Y]   LIN ET AL.: "Tissue Plasminogen Activator Activates NF-kB through a Pathway Involving Annexin A2/ CD 11b and Integrin-Linked Kinase.", J AM SOC NEPHROL, vol. 23, 7 June 2012 (2012-06-07), pages 1329 - 1338, XP055419819 [Y] 3-9, 14, 19, 24, 26-27, 29-32 * . Abstract, page 1333 col 2 para 1 *

DOI:   http://dx.doi.org/10.1681/ASN.2011111123
ExaminationUS2008274102
 US2013190236
 US2006211075
 JP2013176368
 US2007032411
by applicantUS2006293228
   GUPTA ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1799, 2010, pages 775 - 787
   GILMOREHERSCOVITCH, ONCOGENE, vol. 25, 2006, pages 6887 - 6899 [Y] 12-14 * page 3434 col 2 para 4 *
   KAVITHA ET AL., BIOCHIMIE, vol. 102, 2014, pages 56 - 67 [Y] 22 * , page 2 col 1 para 2, Table 2 *
   "Methods in Cell Biology", vol. XIV, 1976, ACADEMIC PRESS, pages: 33
   BOWLES ET AL., ARTHRITIS RHEUMATOL, vol. 66, no. 3, 2014, pages 637 - 46
   NIEDERBERGERGEISSLINGER, FASEB J, vol. 22, no. 10, 2008, pages 3432 - 42 [Y] 3-9, 14, 19, 24, 26-27, 29-32 * . Abstract, page 1333 col 2 para 1 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.